Trial Profile

A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Revakinagene taroretcel (Primary)
Indications Retinal telangiectasis
Focus Therapeutic Use
Sponsors GNT Pharma

Most Recent Events

18 Mar 2025 Status changed from not yet recruiting to recruiting.
20 May 2024 Planned End Date changed from 29 Dec 2025 to 24 Jul 2026.
20 May 2024 Planned primary completion date changed from 23 Sep 2025 to 27 Apr 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com